Álvarez Beatriz, Montero Angel, Valero Jeannette, López Mercedes, Ciérvide Raquel, Hernando Ovidio, Sánchez Emilio, de la Casa Miguel Angel, Chen-Zhao Xin, García-Aranda Mariola, Martinez Ana, Alonso Rosa, Sánchez Miguel, Fernández-Letón Pedro, Rubio Carmen
Department of Radiation Oncology, HM Hospitales, c/Oña 10, 28050, Madrid, Spain.
Universidad Camilo José Cela of Madrid, Madrid, Spain.
Clin Transl Oncol. 2025 Apr 27. doi: 10.1007/s12094-025-03936-8.
Painful musculoskeletal disorders (PMDs) represent an increasing public health concern, particularly among aging populations. When conservative therapies prove insufficient, low-dose radiotherapy (LDRT) has emerged as a non-invasive and effective treatment alternative. Despite growing clinical evidence supporting its efficacy, LDRT remains underutilized due to persistent skepticism and the absence of standardized clinical guidelines.
This review synthesizes current evidence on the use of LDRT for PMDs, focusing on its biological mechanisms, optimal dosing regimens, clinical efficacy, and safety profile. Attention is given to dose fractionation strategies, timing of re-irradiation, and technological advancements that enhance treatment precision.
LDRT provides pain relief in 60-90% of treated cases, with the most favorable results achieved using fraction doses between 0.3 and 0.7 Gy. Its anti-inflammatory effects are mediated through immune modulation, reduced proinflammatory cytokine expression, and promotion of tissue repair. Re-irradiation performed 10-12 weeks after the initial cycle may be beneficial in patients experiencing symptom persistence or recurrence. Long-term follow-up data confirm sustained efficacy and indicate a minimal risk of radiation-induced malignancies in older adults.
LDRT is a safe and effective treatment option for PMDs, especially in patients unresponsive to conventional therapies. To facilitate its broader adoption, this review underscores key clinical evidence and proposes practical considerations for integrating LDRT into multidisciplinary pain management protocols.
疼痛性肌肉骨骼疾病(PMDs)日益引起公众健康关注,在老龄化人群中尤为如此。当保守治疗证明不足时,低剂量放疗(LDRT)已成为一种非侵入性且有效的治疗选择。尽管越来越多的临床证据支持其疗效,但由于持续的怀疑态度以及缺乏标准化临床指南,LDRT的使用仍未得到充分利用。
本综述综合了目前关于LDRT用于PMDs的证据,重点关注其生物学机制、最佳给药方案、临床疗效和安全性。关注剂量分割策略、再次放疗的时机以及提高治疗精度的技术进步。
LDRT在60-90%的治疗病例中提供疼痛缓解,使用0.3至0.7 Gy之间的分次剂量可取得最理想的效果。其抗炎作用通过免疫调节、降低促炎细胞因子表达以及促进组织修复来介导。在初始周期后10-12周进行再次放疗可能对症状持续或复发的患者有益。长期随访数据证实了持续疗效,并表明老年患者发生放射性恶性肿瘤的风险最小。
LDRT是治疗PMDs的一种安全有效的选择,尤其是对传统治疗无反应的患者。为促进其更广泛的应用,本综述强调了关键临床证据,并提出了将LDRT纳入多学科疼痛管理方案的实际考虑因素。